Wall Street Journal @WSJ reporter covering pharma. Past: @DowJones Newswires, @LansReporter, Montgomeryville Spirit. 215-881-7127, peter.loftus@wsj.com

Panel Recommends FDA Approval of Remicade Knockoff

wsj.com — A U.S. regulatory panel vote on Tuesday is a win for companies developing lower-cost copies of pricey biotechnology drugs, but it could be a while before patients see some of them. An advisory panel to the U.S. Food and Drug Administration voted to recommend the agency approve the sale of a knockoff version of Johnson & Johnson's arthritis drug Remicade, which had U.S.
Feb 09, 2016

FDA panel backing of Remicade copy is good news for biosimilars. But IP battles could delay some from reaching mkt. on.wsj.com/1KDRHUT

Feb 09, 2016

AbbVie has 70 patents on Humira, the largest IP portfolio ever 4 a single drug. @loftus on tough road 4 biosimilars. on.wsj.com/1KDRHUT

Feb 09, 2016

FDA panel vote on Remicade copy bodes well for US biosimilars, but biotech patents could complicate things on.wsj.com/1KDRHUT via @WSJ

Feb 10, 2016

Panel Recommends FDA Approval of Remicade Knockoff - WSJ ow.ly/Y9BBS

Show 4 more tweets from Stefanie Ilgenfritz, Stefanie Ilgenfritz and others...

FDA OK’s Merck’s new hepatitis C drug

marketwatch.com — The U.S. Food and Drug Administration approved Merck & Co.'s new treatment for hepatitis C, the latest entrant in a booming market for drugs for the viral infection - a market now dominated by Gilead Sciences Inc. Merck's treatment, Zepatier, is a once-daily, single-tablet combination of two drugs, grazoprevir and elbasvir.

FDA Approves Merck’s New Hepatitis C Treatment

wsj.com — The U.S. Food and Drug Administration approved Merck & Co.'s new treatment for hepatitis C, the latest entrant in a booming market for drugs for the viral infection-a market now dominated by Gilead Sciences Inc. Merck's treatment, Zepatier, is a once-daily, single-tablet combination of two drugs, grazoprevir and elbasvir.
Jan 28, 2016

Merck sets wholesale price for its hepC drug at a 35% discount to rivals Gilead & AbbVie. on.wsj.com/1PWvFJm via @loftus

Merck to Pay $830 Million to Settle Vioxx Shareholder Suit

wsj.com — Merck & Co. on Friday said it had agreed to pay more than $830 million to settle a lawsuit filed by shareholders who argued that the company had misled them by downplaying data regarding the former painkiller Vioxx.
Jan 15, 2016

Merck to pay another $830 million over Vioxx, this time to settle shareholder suit on.wsj.com/1ldYb0Q via @WSJ $MRK

Jan 15, 2016

RT @Loftus: Merck to pay another $830 million over Vioxx, this time to settle shareholder suit on.wsj.com/1ldYb0Q via @WSJ $MRK

Jan 15, 2016

Merck pulled Vioxx from market 11 yrs ago, but financial penalties keep coming. Now up to more than $6 bn. on.wsj.com/1ldYb0Q @loftus

Drugmakers jack up prices despite government pressure

marketwatch.com — Drugmakers didn't let up on price increases with the start of a new year, demonstrating the industry's pricing power in the face of mounting criticisms of prescription costs in the U.S. Pfizer Inc. , Amgen Inc. , Allergan PLC , Horizon Pharma PLC and others have raised U.S.

Drugmakers Raise Prices Despite Criticisms

wsj.com — Drugmakers didn't let up on price increases with the start of a new year, demonstrating the industry's pricing power in the face of mounting criticisms of prescription costs in the U.S. Pfizer Inc., Amgen Inc., Allergan PLC, Horizon Pharma PLC and others have raised U.S.
Jan 10, 2016

Drugmakers keep raising prices despite mounting criticisms on.wsj.com/1ZVAqdw via @WSJ #JPM16 $PFE $ACOR $AGN

Jan 11, 2016

RT @Loftus: Drugmakers keep raising prices despite mounting criticisms on.wsj.com/1ZVAqdw via @WSJ #JPM16 $PFE $ACOR $AGN

Jan 11, 2016

Drugmakers keep raising prices despite mounting criticisms on.wsj.com/1ZVAqdw via @WSJ

Show 21 more tweets from David Nather, Charles Ornstein and others...

Surge in Prescription Costs Hit Medicare in 2014

wsj.com — Hefty price increases for a number of prescription drugs contributed to higher spending by the U.S. Medicare program in 2014, according to new government data released Monday. The Centers for Medicare and Medicaid Services identified at least five drugs that were covered under Medicare's Part D drug benefit and had increases of 100% or more in cost per unit from 2013 to 2014.
Dec 21, 2015

Surge in prescription costs hit Medicare in 2014; CMS posts new drug cost 'dashboard': on.wsj.com/1QV7Q8N via @WSJ

Dec 22, 2015

CMS highlights at least 5 drugs that had price increase of 100% or more in 2014. Top of the list: Vimovo. on.wsj.com/1QV7Q8N @Loftus

Dec 22, 2015

RT @Loftus: Surge in prescription costs hit Medicare in 2014; CMS posts new drug cost 'dashboard': on.wsj.com/1QV7Q8N via @WSJ

Dec 22, 2015

RT @betswrites: More on surging drug prices: how Medicare was affected in 2014. @Loftus. on.wsj.com/1QV7Q8N

Dec 22, 2015

More on surging drug prices: how Medicare was affected in 2014. @Loftus. on.wsj.com/1QV7Q8N

Show 4 more tweets from Jonathan Rockoff, Jonathan Rockoff and others...

Employers Battle Drug Costs

wsj.com — Rising drug costs are forcing tough decisions on those who foot the bill for much of American health care: employers. The pinch is most acute for the many large employers that, like the University of Minnesota, are self-insured-hiring an insurance company to administer benefits but paying the bill themselves.
Dec 19, 2015

RT @walidgellad: Drug costs are much more than 10% of spending for private insurance, and are growing. Great @Loftus story. on.wsj.com/1YrfNmO via WSJ

Dec 19, 2015

RT @Loftus: As employers battle rising drug costs, workers feel the pinch on.wsj.com/1YrfNmO via @WSJ pic.twitter.com/ywgsgEidFm

Show 23 more tweets from Jonathan Rockoff, Stefanie Ilgenfritz and others...

Lilly to charge $11,430 a month for cancer drug

marketwatch.com — Eli Lilly & Co. said Friday its new lung-cancer drug will cost about $11,430 a patient a month in the U. S.--well above what a group of doctors say is a fair price that reflects what they call the drug's modest benefit. A Lilly spokeswoman said Friday that the price for Portrazza, which received marketing approval from U.S.
Dec 11, 2015

Lilly $LLY to charge $11,430/mo. for cancer drug that extends median life 6-7 weeks more than chemo treatments on.mktw.net/1mfBB97

Dec 12, 2015

Price for modest benefit of new Lilly cancer drug: $11,430 a month. marketwatch.com/story/lilly-to…

Dec 12, 2015

RT @MarketWatch: Eli Lilly says its new cancer drug will cost $11,430 a month, well above what a group of doctors say is a fair price on.mktw.net/1J156QI

Lilly’s Lung-Cancer Drug Portrazza to Cost $11,430 a Month

wsj.com — Eli Lilly & Co. said Friday its new lung-cancer drug will cost about $11,430 a patient a month in the U. S.-well above what a group of doctors say is a fair price that reflects what they call the drug's modest benefit. A Lilly spokeswoman said Friday that the price for Portrazza, which received marketing approval from U.S.
Dec 11, 2015

Lilly says lung-cancer drug Portrazza to cost $11,430 a month in U.S. on.wsj.com/1NgGSGn via @WSJ $LLY

Dec 11, 2015

RT @Loftus: Lilly says lung-cancer drug Portrazza to cost $11,430 a month in U.S. on.wsj.com/1NgGSGn via @WSJ $LLY

Dec 11, 2015

RT @Loftus: Lilly says lung-cancer drug Portrazza to cost $11,430 a month in U.S. on.wsj.com/1NgGSGn via @WSJ $LLY

Dec 11, 2015

$LLY keeping the attention focused on hi prices for mediocre cancer drugs. Potrazza $11,430/month via @Loftus wsj.com/articles/lilly…

Dec 11, 2015

Lilly says lung-cancer drug to cost $11,430/mo in U.S. -- about six times more than cancer docs say it should cost. on.wsj.com/1NgGSGn

Show 9 more tweets from Stephen Wisnefski, Matthew Herper and others...
More Articles →
Feb 13, 2016

Philly is letting skateboarders have one last crack at a famous but long-forbidden destination before it's renovated twitter.com/phillymag/stat…

Feb 12, 2016

RT @stefaniei: Fighting the ‘Cockroach of Mosquitoes,’ Aedes aegypti, which carries dengue, zika and more. on.wsj.com/1o4BQEx pic.twitter.com/BxvDfazilz

Feb 12, 2016

Lilly's patent for giving cancer drug Alimta with vitamins may not block generics in parts of Europe $LLY investor.lilly.com/releasedetail.…

Feb 11, 2016

RT @PhillyInquirer: Taxi drivers are once again protesting against ride-sharing services operating in the city: bit.ly/1o7lVpG pic.twitter.com/DVAwNtTQ9g

Feb 11, 2016

RT @jonathanrockoff: $MYL falls 15% as Wall Street reacts to ~92% premium paid in $7.2bn $MEDAA deal and disappointing sales of top-selling product EpiPen.

Feb 11, 2016

RT @KaiserFamFound: Compared to similar countries, US has highest rate of years lost due to injuries from #guns kaiserf.am/1Tdqyeh pic.twitter.com/XJSBd2O9Pj

Feb 09, 2016

FDA panel vote on Remicade copy bodes well for US biosimilars, but biotech patents could complicate things on.wsj.com/1KDRHUT via @WSJ

Feb 09, 2016

Panel recommends that FDA approve knockoff version of J&J arthritis drug Remicade on.wsj.com/1KDRHUT via @WSJ


Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.